Novel Treatment Advances and Approaches in the Management of Advanced Non-Small Cell Lung Cancer (NSCLC)

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2020 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from November 1, 2020 to March 1, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
AstraZeneca, Bristol-Myers Squibb, and Merck Sharp & Dohme Corp.

Non small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. Lung cancer is by far the leading cause of cancer death among both men and women. More people die of lung cancer than of colon, breast, and prostate cancers combined. As more comprehensive information has been gathered regarding tumor characterization, treatment modalities for NSCLC have expanded to include agents with more specific targets, especially around EGFR mutation–positive NSCLC. The use of histologic subtypes and molecular biomarker assessment in NSCLC has resulted in therapeutic paradigms that can be optimized for individual patients based on unique characteristics of their cancer.

NSCLC is often diagnosed at an advanced stage, and despite progress in early detection and treatment, prognosis is poor. Historically, treatment has included a variety of modalities such as surgery, chemotherapy, and radiotherapy. More recently, therapeutic options for NSCLC have evolved to include targeted agents that have the ability to individualize treatment for patients with advanced NSCLC. The expanding role of these therapies and the concept of tailoring therapies based on clinical and molecular markers are transforming the treatment of NSCLC. Molecular testing has now become a critical part of selecting treatment for patients with advanced NSCLC. The first-line management of EGFR-mutated advanced NSCLC has begun to change with new indications bringing more options to the table. With this in mind, it is imperative that oncologists, medical directors and nurses are informed about these new treatments options, as well as the importance of molecular testing when selecting a treatment regimen.

Upon completion of this activity, participants will be able to:

  • Explore safety and efficacy profiles of current and emerging immunotherapies, both alone and in combination, in the management of advanced NSCLC

  • Assess the role of combination immunotherapy in the first-line treatment of patients with advanced NSCLC

  • Compare current and emerging first-line treatment strategies for advanced EGFR-mutated advanced NSCLC focusing on safety, efficacy, and the individualization of therapy based on tumor-specific and patient-specific factors

  • Discuss evolving uses for biomarkers to practically inform clinical trial design and decision-making concerning treatment strategies in NSCLC

  • Examine methods to enable optimal cost management of immunotherapy combinations and EGFR-TKIs to be realized by multiple NSCLC stakeholders including managed care organizations


Faculty: Joshua Bauml, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Perelman School of Medicine
University of Pennsylvania


Dr. Bauml serves as a consultant for AstraZeneca, Ayala, BMS, Boehringer Ingleheim, Celgene, Clovis, Guardant Health, Genentech, Inivata, Janssen, Merck, Regeneron, and Takeda. He has received grants/research support from AstraZeneca, Bayer, Carevive Systems, Clovis, Janssen, Merck, Novartis, and Takeda. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
AstraZeneca, Bristol-Myers Squibb, and Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue